Cardiovascular Disease Risk Tests — CPB 0381 | AETNA Coverage Update

TL;DR: Aetna, a CVS Health company, modified CPB 0381 covering cardiovascular disease risk tests, effective November 27, 2025. Here's what billing teams need to know about medical necessity criteria, covered codes, and what Aetna now considers experimental.

Aetna's cardiovascular disease risk test coverage policy (CPB 0381) governs reimbursement for a wide range of cardiac biomarkers, imaging tests, and genetic panels — including hs-CRP, apolipoprotein B, homocysteine, and dozens of associated CPT codes. This update draws clear lines between what qualifies for coverage and what Aetna now calls experimental or unproven. If your practice bills for any cardiovascular risk stratification tests — CPT 83698 for Lp-PLA2, CPT 83704 for lipoprotein particle quantitation, CPT 81493 for gene expression profiling, or any of the 100+ codes in this policy — you need to audit your documentation before claims go out the door.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna, a CVS Health company
Policy	Cardiovascular Disease Risk Tests
Policy Code	CPB 0381
Change Type	Modified
Effective Date	November 27, 2025
Impact Level	High
Specialties Affected	Cardiology, Internal Medicine, Primary Care, Clinical Laboratory, Endocrinology, Hematology
Key Action	Audit documentation for hs-CRP, apoB, and homocysteine claims against the updated three-part criteria before submitting

---

Aetna Cardiovascular Disease Risk Test Coverage Criteria and Medical Necessity Requirements 2025

The Aetna cardiovascular disease risk test coverage policy breaks medical necessity into three distinct analytes. Each has its own criteria, and they don't overlap. Getting one right doesn't mean the others follow the same logic.

High-Sensitivity C-Reactive Protein (hs-CRP)

Aetna covers hs-CRP testing only when a member meets all three of the following criteria simultaneously:

#	Covered Indication Copy
1	Two or more major CHD risk factors (age ≥45 for men or ≥55 for women; current cigarette smoking; family history of premature CHD; hypertension with BP ≥140 mm Hg or on antihypertensive medication; HDL <40 mg/dL)
2	LDL cholesterol between 100–130 mg/dL
3	Intermediate cardiovascular risk — specifically 10–20% CHD risk over 10 years using Framingham point scoring

All three criteria must be present. If LDL is below 100 or above 130, the claim won't hold. If Framingham risk is below 10% or above 20%, same result. Your clinical documentation needs to capture all three explicitly.

Routine hs-CRP screening for the general population is not covered. Using hs-CRP to monitor therapy response is not covered. These are flat exclusions — prior authorization won't save them.

Note: The source data provided for CPB 0381 does not enumerate a specific CPT code for hs-CRP testing. Confirm the correct billing code against the full CPB 0381 document at app.payerpolicy.org/p/aetna/0381 before submitting claims.

Apolipoprotein B (apoB)

Aetna covers apoB measurement for high-risk patients when LDL cholesterol goals have already been reached and the question is whether further intervention is needed. The coverage hinge here is goal attainment, not just risk level.

For patients with known CVD or diabetes, coverage applies when LDL-C is below 70 mg/dL and non-HDL is below 100 mg/dL. For patients with other risk factors, the thresholds are LDL-C below 100 mg/dL and non-HDL below 130 mg/dL.

To qualify as high-risk, the patient must have diabetes mellitus, known CVD, or at least two of the following: current smoking, family history of premature CVD, or hypertension (BP ≥140 mm Hg or on antihypertensive medication).

If your cardiologists are ordering apoB as part of initial workup rather than post-goal assessment, those claims are at high risk for denial. The policy is explicit: this test is for deciding whether to intensify therapy after goals are reached.

Note: The source data provided for CPB 0381 does not enumerate a specific CPT code for apoB measurement. Confirm the correct billing code against the full CPB 0381 document at app.payerpolicy.org/p/aetna/0381 before submitting claims.

Homocysteine Testing

Aetna covers homocysteine testing for three specific indications:

#	Covered Indication Copy
1	Evaluating homocystinuria (cystathionine beta synthase deficiency)
2	Evaluating unexplained coagulation disorders — specifically conditions like deep venous thrombosis or pulmonary embolism
3	Evaluating borderline vitamin B12 deficiency

That's it. Using homocysteine to assess CHD or stroke risk is explicitly experimental under this policy. Ordering it for women with recurrent pregnancy loss is experimental. Homocysteine/lipoprotein(a) testing for arterial thrombosis in newborns is experimental.

The real issue here is that homocysteine as a cardiac risk marker has significant clinical support in some guidelines — but Aetna is holding the line that this use is unproven for reimbursement purposes. If your physicians are ordering it for cardiac risk stratification, expect denial.

Note: The source data provided for CPB 0381 does not enumerate a specific CPT code for homocysteine testing. Confirm the correct billing code against the full CPB 0381 document at app.payerpolicy.org/p/aetna/0381 before submitting claims.

---

Aetna Cardiovascular Disease Risk Test Exclusions and Non-Covered Indications

Aetna draws a hard line on several categories under CPB 0381. These aren't gray areas.

Explicitly experimental or unproven:

Explicitly not covered for cardiovascular disease risk (flagged directly in the code table):

Several emerging cardiovascular biomarker tests carry a no-specific-coverage designation under this policy. This includes CPT 0308U (three-protein CAD panel), CPT 0309U (four-protein cardiovascular disease panel), CPT 0401U and CPT 0439U (coronary heart disease genetic panels), CPT 0466U (CAD genome-wide association panel), and CPT 0716T (cardiac acoustic waveform analysis with CAD risk generation). These codes are grouped in the policy under the CADence System, QuantaFlo System, and Vicorder device designation — Aetna assigns no specific coverage to them.

Devices like the CADence System, QuantaFlo System, and Vicorder device fall under the same no-specific-coverage designation throughout this policy. If your practice has invested in any of these, reimbursement under CPB 0381 is not available.

---

Coverage Indications at a Glance

---

Aetna Cardiovascular Disease Risk Test Billing Guidelines and Action Items 2025

This policy has over 100 affected CPT codes. The documentation requirements are specific. Here's what to do before submitting claims under CPB 0381.

Copy Action Items

If your practice has a high volume of cardiovascular risk testing across multiple Aetna plan types, loop in your compliance officer before the November 27 effective date. The breadth of this policy — 100+ CPT codes, explicit experimental designations, device-level exclusions — creates real exposure for practices that haven't mapped their order sets to Aetna's criteria.

---

CPT, HCPCS, and ICD-10 Codes for Cardiovascular Disease Risk Tests Under CPB 0381

Covered CPT Codes (When Selection Criteria Are Met)

Not Covered / No Specific Coverage CPT Codes

Note: The policy data includes 22 additional CPT codes in the molecular pathology tier series (81407–81408 range and others) designated as covered if selection criteria are met. Review the full CPB 0381 document at app.payerpolicy.org/p/aetna/0381. for the complete list.

The policy also includes 2,727 ICD-10-CM diagnosis codes. Given the volume, reference the full policy at app.payerpolicy.org/p/aetna/0381 for the complete ICD-10 list.

---